Walleye Trading’s AbCellera Biologics ABCL Stock Holding History

Walleye Trading’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.4K	Sell	400 -96,800	-100%	-$348K	﹤0.01%	4011
2025 Q4	$332K	Buy	97,200 +10,700	+12%	+$47.8K	﹤0.01%	3085
2025 Q3	$435K	Buy	+86,500	New	+$381K	﹤0.01%	2835
2024 Q1	–	Sell	-15,700	Closed	-$89.6K	–	4671
2023 Q4	$89.6K	Sell	15,700 -1,700	-10%	-$7.88K	﹤0.01%	4185
2023 Q3	$80K	Buy	17,400 +5,800	+50%	+$35.3K	﹤0.01%	4056
2023 Q2	$74.9K	Buy	11,600 +11,100	+2,220%	+$75.7K	﹤0.01%	3847
2023 Q1	$3.77K	Buy	+500	New	+$4.54K	﹤0.01%	4537
2022 Q4	–	Sell	-9,300	Closed	-$92K	–	4904
2022 Q3	$92K	Buy	+9,300	New	+$102K	﹤0.01%	4076

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Trading's ABCL Position: Q1 2026 in Review

Walleye Trading reduced its AbCellera Biologics (ABCL) stake by 22% in Q1 2026, selling an estimated $7.8K and leaving 7,678 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3810.

Walleye Trading first reported a position in ABCL in Q3 2022 and has held it in 7 quarters since. The position peaked at $361K in Q3 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Walleye Trading held 7,678 shares of AbCellera Biologics worth $26.8K as of Q1 2026.
Walleye Trading sold 2,168 AbCellera Biologics shares in Q1 2026, an estimated $7.8K.
AbCellera Biologics made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #3810 holding.
Walleye Trading first reported a position in AbCellera Biologics in Q3 2022 and has held it in 7 quarters since.
Walleye Trading's AbCellera Biologics position peaked at $361K in Q3 2022.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.